BeiGene narrows Q1 loss, revenue jumps 50.2%

Biotech firm BeiGene reported RMB 8.05 billion in revenue for Q1 2025, a 50.2% YoY increase, while narrowing its net loss to RMB 94.5 million. Gross margin improved by 2.74 percentage points to 85.86%, and operating expenses declined as a share of revenue. Analysts forecast full-year profit of RMB 298 million.